MyFinsight
Home
Blog
About
Net income (loss)
attributable to common...
-$23,206,372
(-199.33%↓ Y/Y)
Net income (loss)
-$19,424,654
(-163.36%↓ Y/Y)
Preferred stock accretion
$3,503,222
(9.70%↑ Y/Y)
Preferred stock dividends
$278,496
(-75.35%↓ Y/Y)
Total other income
(expense), net
-$12,570,941
(-135.88%↓ Y/Y)
Loss from operations
-$6,853,713
(-56.55%↓ Y/Y)
Gain on related party
investment qcls
$2,089,000
Change in fair value of
convertible note receivable ...
$1,304,000
(38.58%↑ Y/Y)
Change in fair value of
derivative liability
$1,117,000
(-48.86%↓ Y/Y)
Interest income
$733,351
(-48.19%↓ Y/Y)
Dividend income
$380,682
Gain on legal
settlement re-fair value of...
$106,000
Change in fair value of
investment qcls
-$7,732,000
Change in fair value of
warrant liability
-$4,746,135
(-145.43%↓ Y/Y)
Change in fair value of
warrant asset femasys
-$2,581,000
(-23.43%↓ Y/Y)
Total operating
expenses
$6,853,713
(56.55%↑ Y/Y)
Change in fair value of
warrant assets qcls
-$1,379,000
Issuance costs series c
convertible preferred stock...
-$1,234,553
Unrealized gain (loss) on
marketable securities
-$412,306
(-721.73%↓ Y/Y)
Loss on issuance of
series c preferred...
-$215,000
Other expense, net
-$980
(-1.55%↓ Y/Y)
General and
administrative
$4,912,985
(24.71%↑ Y/Y)
Intangible asset
impairment
$1,549,427
Research and development
costs
$391,301
(-10.75%↓ Y/Y)
Back
Back
Income Statement
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)
source: myfinsight.com